Loading…
Clinical-stage biotech developing long-acting antibody drugs for psoriasis and other skin/inflammatory diseases.
Clinical-stage biotech developing long-acting antibody drugs for psoriasis and other skin/inflammatory diseases.
Moat: none (IP / patents). Pre-commercial; strategy is to engineer less-frequent-dosing antibodies against validated psoriasis targets.
Headquarters: Waltham, Massachusetts, United States · Founded: 2023 · Employees: 68
Size Oruka Therapeutics (ORKA) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $6.81B, the 974th largest of 3,117 United States companies the cockpit tracks. Shares closed at $102.86 on 6 Nov 2026.
Performance Over six months the shares gained 59.2%, against -0.2% for the median peer and -1.1% for the United States market (cap-weighted) — 2nd highest of 21 in its peer set.
Capital Return on invested capital runs 56.1 points below its cost of capital (6.4% WACC).
Short interest Short interest is 9.2% of the free float (15 Oct 2026).
Next results Next results expected around 18 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | -$134,000 | -$83,000 | -$27,000 | -$111,000 | -$114,000 |
| EBITDA | -$155M | -$122M | -$88.1M | -$7.18M | -$9.73M |
| Net income | -$133M | -$105M | -$83.7M | -$5.34M | -$9.93M |
| Free cash flow | -$101M | -$88.4M | -$58.0M | -$5.01M | -$10.9M |
| Capital expenditure | $235,000 | $209,000 | $189,000 | $0 | $2,000 |
| Total debt | $2.55M | $1.93M | $968,000 | $280,000 | $383,000 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Oruka Therapeutics ORKA | $6.81B | +59% | n/a | n/a | n/a | n/a |
| Johnson & Johnson JNJ | $665B | +26% | +8% | 26% | 7.0× | 3.5% |
| Novartis NOVN.SW | $298B | +15% | -4% | 30% | 6.3× | 1.7% |
| AbbVie ABBV | $515B | +45% | +11% | 36% | 8.9× | -0.1% |
| Lilly (Eli) LLY | $1.27T | +43% | +46% | 51% | 15.2× | 5.9% |
| Bristol Myers Squibb BMY | $127B | +12% | +4% | 33% | 3.2× | -12.9% |
| Alumis ALMS | $805M | -27% | -63% | -5,480% | 45.8× | n/a |
| Takeda Pharmaceutical 4502.T | $66.4B | +24% | +6% | 18% | 3.1× | 3.0% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ORKA | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +33.1% | +2.7% | highest of 21 |
| 6-month return | +59.2% | -0.2% | 2nd highest of 21 |
| Distance from 52-week high | -11.0% | -16.4% | 9th highest of 21 |
| ROIC minus cost of capital | -56.1 pp | +1.3 pp | 3rd lowest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Oruka Therapeutics ORKA | United States | $6.81B | +59% | n/a | n/a | n/a | n/a | n/a |
| RemeGen 688331.SS | China | $6.90B | -26% | +272% | 61% | 4.9× | 2.8% | +303.3% |
| Alkem Laboratories ALKEM.NS | India | $6.67B | -5% | +13% | 17% | 4.2× | 24.3% | +10.7% |
| ONO Pharmaceutical 4528.T | Japan | $7.01B | +2% | -2% | 22% | 2.0× | -8.2% | +10.8% |
| Amneal Pharmaceuticals AMRX | United States | $7.01B | +53% | +9% | 17% | 3.2× | 15.2% | +8.7% |
| Ionis Pharmaceuticals IONS | United States | $6.55B | -48% | -7% | -68% | 7.7× | n/a | n/a |
| China Resources Sanjiu Medical & Pharmaceutical 000999.SZ | China | $6.48B | 0% | +4% | 14% | 1.9× | -6.3% | +18.4% |
| Gan & Lee Pharmaceuticals 603087.SS | China | $6.40B | +21% | +14% | 20% | 8.8× | n/a | n/a |
| Samsung Epis 0126Z0.KS | South Korea | $6.39B | -36% | n/a | -25% | 34.5× | n/a | n/a |
| Huadong Medicine 000963.SZ | China | $7.29B | -17% | +2% | 9% | 1.1× | -2.7% | +5.3% |
| Bachem BANB.SW | Switzerland | $7.32B | +3% | +5% | 19% | 8.7× | n/a | n/a |
| Kiniksa Pharmaceuticals International KNSA | United States | $7.37B | +60% | +58% | 14% | 7.2× | 9.9% | +45.5% |
| Biocon BIOCON.NS | India | $6.28B | -4% | +6% | 8% | 4.3× | n/a | n/a |
| Cytokinetics CYTK | United States | $7.46B | -30% | -21% | -1,046% | 111.8× | n/a | n/a |
| Belite Bio, Inc. ADR BLTE | United States | $6.20B | 0% | n/a | n/a | n/a | n/a | n/a |
| Grifols GRF.MC | Spain | $7.49B | +23% | 0% | 16% | 2.3× | 6.8% | +7.1% |
| Ligand Pharmaceuticals LGND | United States | $6.12B | +38% | +1% | 14% | 26.9× | 57.8% | +7.5% |
| Mirum Pharmaceuticals MIRM | United States | $6.12B | -13% | +42% | -21% | 9.7× | n/a | n/a |
| Alkermes Public ALKS | United States | $7.71B | +31% | +15% | 5% | 4.9× | 31.5% | +7.3% |
| Glenmark Pharmaceuticals GLENMARK.NS | India | $7.73B | +9% | +33% | 20% | 4.1× | 20.0% | +9.4% |
| Praxis Precision Medicines PRAX | United States | $7.75B | -16% | -100% | n/a | n/a | n/a | n/a |